Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Murray Lappe
AddedMar 31, 2024
UpdatedMay 31, 2026
Murray Lappe

Murray Lappe

CEO, Ocutronics

CrunchbaseLinkedIn

Murray Lappe's Career

Ocutronics
Ocutronics

Denver, CO, US

CEO· C-Suite · Management
Emerge Diagnostics
Emerge Diagnostics

Carlsbad, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Murray Lappe's Career

Ocutronics
Ocutronics
Angel$125k302002Denver, CO, US
CEO· C-Suite · Management

Leadership at Ocutronics

Robert E. LevineRobert E. LevineFounder

Similar to Ocutronics

OcuSciencesOcuSciencesAnn Arbor, MI, USMedical Devicesest. 2008OcuSciencesAnn Arbor, MI, US · est. 2008

OcuSciences: Innovating non-invasive ocular imaging devices for early detection and treatment of diabetes-related eye conditions.

Seed · $900k7
OptovueOptovueFremont, CA, USOphthalmic Devicesest. 2003OptovueFremont, CA, US · est. 2003

Optovue, Inc.: Global provider of innovative ophthalmic devices for ocular disease diagnosis and therapy.

Public · $40.5M133
Retina TechnologiesRetina TechnologiesNew York City, NY, USMedical Devicesest. 2018Retina TechnologiesNew York City, NY, US · est. 2018

Retina Technologies: Making vision screening accessible with portable, modular medical devices.

Pre-Seed · $333k8
Bioxytech RetinaBioxytech RetinaRichmond, CA, USMedical Devicesest. 2015Bioxytech RetinaRichmond, CA, US · est. 2015

Bioxytech Retina, founded in 2015, pioneers non-invasive optical devices for diabetes diagnosis.

Pre-Seed · $1.2M5
Emerge Diagnostics
Emerge Diagnostics
Pre-Seed$9.3M362012Carlsbad, CA, US
Board Member· Board

Leadership at Emerge Diagnostics

Robert ThompsonRobert ThompsonBoard Member
Bret OettmeierBret OettmeierCEO
Mary Rose ReastonMary Rose ReastonCo-Founder
Phil ReastonPhil ReastonCo-Founder

Similar to Emerge Diagnostics

Haystack DxHaystack DxLowell, MA, USDiagnostic Solutionsest. 2018Haystack DxLowell, MA, US · est. 2018

Haystack Dx offers affordable, innovative diagnostic solutions for neuromuscular disorders, enhancing patient care.

Angel · $250k3
Jan MedicalJan MedicalMountain View, CA, USMedical Devicesest. 2003Jan MedicalMountain View, CA, US · est. 2003

Developing medical devices to enhance brain disorder diagnostics and therapy acceleration.

Series C · $11M17
Empowered DiagnosticsEmpowered DiagnosticsPompano Beach, FL, USDiagnostic Testsest. 2017Empowered DiagnosticsPompano Beach, FL, US · est. 2017

Empowered Diagnostics: Reliable, affordable, high-quality diagnostic tests for informed health decisions.

Seed · $4.7M13
InstadiagnosticsInstadiagnosticsPhiladelphia, PA, USDiagnostic Testsest. 2015InstadiagnosticsPhiladelphia, PA, US · est. 2015

Instadiagnostics: Bringing rapid, quantitative, bedside diagnostic testing to patients.

Pre-Seed · $6.7M7

Murray Lappe's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Murray Lappe

Charbel RizkCharbel RizkCEO · OculiAlex KinnierAlex KinnierCEO · UpsideBrent SaundersBrent SaundersCEO · Bausch & LombAnthony SampietroAnthony SampietroCo-Founder · Ocular ScienceSteven HongSteven HongCo-Founder · Kumu Networks